Modern obstetrics and gynecology use a wide range of medicines (drugs) when accompanied by pregnancy and childbirth (miscarriage, discoordination labor, labor pain relief), diseases of the female reproductive system (inflammation, dishormonal disorders, etc.). Among the traditional drugs most widely used antibiotics, NSAIDs, analgesics, antispasmodics, hormones. These drugs, along with the achievement of rapid and pronounced therapeutic effects cause different side effects, and have a number of contra-indications (diseases of the liver, the pancreas, the risk of thrombosis, the development of immunodeficiency, etc.) [12]. In this regard, special attention and care requires the use of drugs in pregnant women and nursing mothers. Also relevant is the increase of efficiency of treatment of many gynecological diseases. All these and many other factors encourage to search for new – more effective and safer treatment approaches and drugs, including pathogenesis [12,22]. The review presents brief characteristics and clinical researches on the use and integrated bioregulatory approach through the use of complex combination bioregulatory medicines (CBM) Viburkol, Limphomiozot, Limphomiozot N in obstetrics and in various diseases and disorders of the female reproductive system [1–3]. The research results show that the inclusion of one or more of the CBM in the traditional treatment help reduce the duration of therapy, a decrease in some side effects, and in some cases rejection of it. In addition, they do not burden for opportunistic diseases, tolerated well and have a favorable safety profile, can be used during pregnancy and lactation [4–22]. Key words: Viburkol, Limphomiozot, Limphomiozot N, bioregulatory approach, combination bioregulatory medicines, obstetrics, gynecology, diseases of the female reproductive system.